Vincenzo Di Noia

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 2

Top Topics

Small Cell Lung Cancer

Chronic Kidney Disease

Ejection Fraction

Prognostic Factors

Top Venues

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Marco Russano, Alessio Cortellini, Raffaele Giusti, Alessandro Russo, Federica Zoratto, Francesca Rastelli, Alain Gelibter, Rita Chiari, Olga Nigro, Michele De Tursi, Sergio Bracarda, Stefania Gori, Francesco Grossi, Melissa Bersanelli, Lorenzo Calvetti, Vincenzo Di Noia, Mario Scartozzi, Massimo Di Maio, Paolo Bossi, Alfredo Falcone, Fabrizio Citarella, Francesco Pantano, Corrado Ficorella, Marco Filetti, Vincenzo Adamo, Enzo Veltri, Federica Pergolesi, Mario Alberto Occhipinti, Linda Nicolardi, Alessandro Tuzi, Pietro Di Marino, Serena Macrini, Alessandro Inno, Michele Ghidini, Sebastiano Buti, Giuseppe Aprile, Eleonora Lai, Marco Audisio, Salvatore Intagliata, Riccardo Marconcini, Davide Brocco, Giampiero Porzio, Marta Piras, Erika Rijavec, Francesca Simionato, Clara Natoli, Marcello Tiseo, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer immunology, immunotherapy : CII (2021)
Vincenzo Di Noia, Ettore D'Argento, Sara Pilotto, Emanuele Vita, Miriam Grazia Ferrara, Paola Damiano, Marta Ribelli, Antonella Cannella, Antonella Virtuoso, Andrea Fattorossi, Giovanni Luca Ceresoli, Michele Milella, Giordano Domenico Beretta, Giampaolo Tortora, Emilio Bria
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. Cancer immunology, immunotherapy : CII 70 (6) (2020)